JP2017522555A - 多形膠芽腫（ｇｂｍ）のためのマーカー及び治療指標 - Google Patents

多形膠芽腫（ｇｂｍ）のためのマーカー及び治療指標 Download PDF

Info

Publication number
JP2017522555A
JP2017522555A JP2016575349A JP2016575349A JP2017522555A JP 2017522555 A JP2017522555 A JP 2017522555A JP 2016575349 A JP2016575349 A JP 2016575349A JP 2016575349 A JP2016575349 A JP 2016575349A JP 2017522555 A JP2017522555 A JP 2017522555A
Authority
JP
Japan
Prior art keywords
gbm
level
subject
tissue
hmox1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016575349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522555A5 (enExample
Inventor
ディマンクリシュナ ゴーシュ、
ディマンクリシュナ ゴーシュ、
チャールズ、 エス． コブス、
チャールズ、 エス． コブス、
ナーザン、 ディー． プライス、
ナーザン、 ディー． プライス、
リーロイ フード、
リーロイ フード、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Systems Biology
Original Assignee
Institute for Systems Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Systems Biology filed Critical Institute for Systems Biology
Publication of JP2017522555A publication Critical patent/JP2017522555A/ja
Publication of JP2017522555A5 publication Critical patent/JP2017522555A5/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2016575349A 2014-06-26 2015-06-26 多形膠芽腫（ｇｂｍ）のためのマーカー及び治療指標 Pending JP2017522555A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017748P 2014-06-26 2014-06-26
US62/017,748 2014-06-26
PCT/US2015/038043 WO2015200823A1 (en) 2014-06-26 2015-06-26 Markers and therapeutic indicators for glioblastoma multiforme (gbm)

Publications (2)

Publication Number Publication Date
JP2017522555A true JP2017522555A (ja) 2017-08-10
JP2017522555A5 JP2017522555A5 (enExample) 2018-08-02

Family

ID=54938849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575349A Pending JP2017522555A (ja) 2014-06-26 2015-06-26 多形膠芽腫（ｇｂｍ）のためのマーカー及び治療指標

Country Status (6)

Country Link
US (1) US20170176439A1 (enExample)
EP (1) EP3161489A4 (enExample)
JP (1) JP2017522555A (enExample)
AU (1) AU2015279660A1 (enExample)
CA (1) CA2953459A1 (enExample)
WO (1) WO2015200823A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019100929A (ja) * 2017-12-05 2019-06-24 国立大学法人金沢大学 膠芽腫マーカー及びその使用
JP2022513349A (ja) * 2018-10-14 2022-02-07 ランタン ファーマ インコーポレイテッド イルジンおよびバイオマーカーを使用した固形腫瘍癌の治療方法
JP2022060333A (ja) * 2017-12-05 2022-04-14 国立大学法人金沢大学 膠芽腫マーカー及びその使用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018177982A1 (en) 2017-03-30 2018-10-04 Administración General De La Comunidad Autónoma De Euskadi Sox1 as a prognostic and predictive biomarker in the treatment of central nervous system tumours
CN107653319B (zh) * 2017-10-27 2020-06-30 中南大学湘雅医院 胶质瘤诊断标志物circ8:61680968|61684188及应用
CN108956997A (zh) * 2017-12-29 2018-12-07 广西壮族自治区人民医院 Cd151蛋白表达量elisa检测方法及试剂盒
CN110211634B (zh) * 2018-02-05 2022-04-05 深圳华大基因科技服务有限公司 一种多组学数据联合分析的方法
CN114267447B (zh) * 2021-09-26 2025-05-06 吴安华 一种预测胶质母细胞瘤免疫微环境、预后及治疗敏感性的基因集及系统和方法
PL446389A1 (pl) * 2023-10-15 2025-04-22 Warszawski Uniwersytet Medyczny Nowe markery do diagnozowania glejaka wielopostaciowego oraz ich zastosowania

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517046A (ja) * 2003-12-24 2007-06-28 サイオス・インコーポレーテツド Ｔｇｆ−ベータ阻害剤による悪性神経膠腫の治療
JP2008546387A (ja) * 2005-06-13 2008-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US20100167939A1 (en) * 2007-03-02 2010-07-01 Kenneth Aldape Multigene assay to predict outcome in an individual with glioblastoma
US20100322949A1 (en) * 2007-04-26 2010-12-23 Ludwig Institute For Cancer Research Ltd. Methods for diagnosing and treating astrocytomas
US20120207753A1 (en) * 2009-08-21 2012-08-16 Centre Hospitalier Universitaire Vaudois Methods of using cd44 fusion proteins to treat cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
US8404437B2 (en) * 2011-03-29 2013-03-26 Taipei Veterans General Hospital MicroRNA as a cancer progression predictor and its use for treating cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007517046A (ja) * 2003-12-24 2007-06-28 サイオス・インコーポレーテツド Ｔｇｆ−ベータ阻害剤による悪性神経膠腫の治療
JP2008546387A (ja) * 2005-06-13 2008-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
US20100167939A1 (en) * 2007-03-02 2010-07-01 Kenneth Aldape Multigene assay to predict outcome in an individual with glioblastoma
US20100322949A1 (en) * 2007-04-26 2010-12-23 Ludwig Institute For Cancer Research Ltd. Methods for diagnosing and treating astrocytomas
US20120207753A1 (en) * 2009-08-21 2012-08-16 Centre Hospitalier Universitaire Vaudois Methods of using cd44 fusion proteins to treat cancer
JP2013502421A (ja) * 2009-08-21 2013-01-24 マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー 癌治療のためのｃｄ４４融合タンパク質の使用方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
TENG, Z.-P. ET AL: "Expression and significance of liver X receptor beta and ATP binding cassette transport protein A1 i", CHINESE JOURNAL OF BIOLOGICALS, vol. 25, no. 8, JPN6019023018, August 2012 (2012-08-01), pages 982 - 984, ISSN: 0004220221 *
TSO, C.-L. ET AL: "Primary Glioblastomas Express Mesenchymal Stem-like Properties", MOLECULAR CANCER RESEARCH, vol. 4, JPN6019023021, September 2006 (2006-09-01), pages 607 - 619, ISSN: 0004058632 *
WANG, C. ET AL.: "Expressions of ATP binding cassette transporter A1 and Heme oxygenase-1 in human glioblastoma and th", CHINESE JOURNAL OF BIOLOGICALS, vol. 25, no. 7, JPN7019001968, July 2012 (2012-07-01), pages 892 - 895, ISSN: 0004058631 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019100929A (ja) * 2017-12-05 2019-06-24 国立大学法人金沢大学 膠芽腫マーカー及びその使用
JP7029745B2 (ja) 2017-12-05 2022-03-04 国立大学法人金沢大学 膠芽腫マーカー及びその使用
JP2022060333A (ja) * 2017-12-05 2022-04-14 国立大学法人金沢大学 膠芽腫マーカー及びその使用
JP7211604B2 (ja) 2017-12-05 2023-01-24 国立大学法人金沢大学 膠芽腫マーカー及びその使用
JP2022513349A (ja) * 2018-10-14 2022-02-07 ランタン ファーマ インコーポレイテッド イルジンおよびバイオマーカーを使用した固形腫瘍癌の治療方法

Also Published As

Publication number Publication date
CA2953459A1 (en) 2015-12-30
AU2015279660A1 (en) 2017-01-19
EP3161489A4 (en) 2018-04-18
WO2015200823A1 (en) 2015-12-30
EP3161489A1 (en) 2017-05-03
US20170176439A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
JP2017522555A (ja) 多形膠芽腫（ｇｂｍ）のためのマーカー及び治療指標
US9746481B2 (en) Biomarkers of brain injury
CN113025713A (zh) 用于预测肿瘤患者对特定抗肿瘤药物的敏感性的生物标志物的应用
Pranatharthi et al. RhoC regulates radioresistance via crosstalk of ROCK2 with the DNA repair machinery in cervical cancer
JP5822309B2 (ja) 統合プロテオーム解析用データ群の生成方法ならびに同生成方法にて生成した統合プロテオーム解析用データ群を用いる統合プロテオーム解析方法、およびそれを用いた原因物質同定方法
WO2010131194A1 (en) Phosphodiesterase 4d7 as marker for malignant, hormone-sensitive prostate cancer
EP3084000A1 (en) Method of diagnosis and treatment
Li et al. Carbonic anhydrase XII is a clinically significant, molecular tumor-subtype specific therapeutic target in glioma with the potential to combat invasion of brain tumor cells
CA2794840A1 (en) Method and kit for cancer diagnosis
Shi et al. Expression and prognostic role of orphan receptor GPR110 in glioma
Huang et al. Long non-coding RNA PSMA3-AS1 promotes glioma progression through modulating the miR-411-3p/HOXA10 pathway
Chen et al. Down‐regulation of miRNA‐27b‐3p suppresses keratinocytes apoptosis in oral lichen planus
EP3835789A1 (en) Biomarker panel for diagnosing colorectal cancer
EP2430189B1 (en) Phosphodiesterase 9a as prostate cancer marker
Gao et al. LMO1 plays an oncogenic role in human glioma associated with NF-kB pathway
Lyu et al. From tuberculosis bedside to bench: UBE2B splicing as a potential biomarker and its regulatory mechanism
US20150338412A1 (en) Composition for diagnosis of lung cancer and diagnosis kit for lung cancer
He et al. Bioinformatics analysis reveals lipid metabolism may play an important role in the SiO2-stimulated rat model
Guo et al. lncRNA HCG11 Promotes Colorectal Cancer Cell Malignant Behaviors via Sponging miR‐26b‐5p
EP2772759B1 (en) Composition for diagnosis of lung cancer
Wu et al. A Risk Model Based on Ferroptosis‐Related Genes OSMR, G0S2, IGFBP6, IGHG2, and FMOD Predicts Prognosis in Glioblastoma Multiforme
Picolo et al. Salivary proteomics profiling reveals potential biomarkers for chronic kidney disease: a pilot study
WO2013045539A1 (en) Marker in diagnosing prostate cancer (pc)
US10288619B2 (en) Biomarkers for human monocyte myeloid-derived suppresor cells
US12297434B1 (en) Biomarker for predicting drug resistance of bruton's tyrosine kinase inhibitors and application thereof

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20170628

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200310